Tradestie Institutional Equity Comparison Engine
ACHV vs CGEN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGEN Overall Edge
CGEN Captures Institutional Edge (2โ2 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin while ACHV counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ACHV trades at 35.3x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CGEN at 12.4x Forward P/E and 41.3% operating margin (+102.1% YoY). In options structure, ACHV sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro) against CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CGEN
ACHV 35.3x vs CGEN 12.4x Fwd P/E
Growth & Margin Winner
CGEN
Op Margin 0.0% vs 41.3% ยท YoY +0.0% vs +102.1%
Momentum & Technical Winner
ACHV
1Y +43.0% vs +23.2% ยท 52W Pos 69% vs 33%
Options & Structure Winner
ACHV
BREAKOUT (23rd %ile IV) vs BREAKDOWN (57th %ile IV)
ACHV
NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap
$692.8M
1M Return
-8.5%
1Y Return
+43.04%
Forward P/E
35.3x
Unified AI Score
56.6 / 100
HOLD
Tech 66.0
Fund 58.0
Flow 57.0
Mom 58.9
CGEN
NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap
$193.2M
1M Return
+2.54%
1Y Return
+23.17%
Forward P/E
12.4x
Unified AI Score
49.8 / 100
HOLD
Tech 53.0
Fund 52.0
Flow 55.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ACHV +43.04%
CGEN +23.17%
Spread: +24.3 pp (ACHV Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ACHV TTM Op. Margin: 0.0%
CGEN TTM Op. Margin: 41.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACHV vs CGEN. Trailing 12-month operating profitability (ACHV 0.0% vs CGEN 41.3%) and valuation multiples (ACHV 35.3x vs CGEN 12.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ACHV | CGEN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $692.8M | $193.2M | Larger Scale | ACHV |
| Trailing P/E Ratio Valuation | 35.3x | 5.2x | Lower Multiple | CGEN |
| Forward P/E Ratio Valuation | 35.3x | 12.4x | Lower Multiple | CGEN |
| Revenue Growth (YoY) Growth | +0.0% | +102.1% | Higher Growth | CGEN |
| Operating Margin (TTM) Profitability | 0.0% | 41.3% | Higher Margin | CGEN |
| Net Profit Margin Profitability | 0.0% | 47.9% | Higher Margin | CGEN |
| Return on Equity (ROE) Capital Efficiency | -845.0% | 57.2% | Higher ROE | CGEN |
| 52-Week Range Position Momentum | 69% ($3โ$9) | 33% ($1โ$3) | Stronger Trend | ACHV |
| Beta / 30D Volatility Risk Regime | 1.73ฮฒ ยท 62% Vol | 1.44ฮฒ ยท 62% Vol | Lower Realized Risk | Tie |
| Unified Institutional Score Composite Signal | 56.6 / 100 (HOLD) | 49.8 / 100 (HOLD) | Higher Composite | ACHV |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ACHV vs CGEN Buy Guide
ACHV
BREAKOUT
125d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
23rd %ile
IV Regime
Compressed (<25th %ile)
CGEN
BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
57th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ACHV nor CGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.